[stock_market_widget type="clock-markets" template="analog" timezone="America/New_York" title="New York" style="font-size: 7px; width: 100px;"] [stock_market_widget type="clock-markets" template="analog" timezone="Europe/London" title="London" style="font-size: 7px; width: 100px;"] [stock_market_widget type="clock-markets" template="analog" timezone="Europe/Brussels" title="Brussels" style="font-size: 7px; width: 100px;"] [stock_market_widget type="clock-markets" template="analog" timezone="Asia/Hong_Kong" title="Hong Kong" style="font-size: 7px; width: 100px;"] [stock_market_widget type="clock-markets" template="analog" timezone="Asia/Tokyo" title="Tokyo" style="font-size: 7px; width: 100px;"] [stock_market_widget type="clock-markets" template="analog" timezone="Australia/Sydney" title="Sydney" style="font-size: 7px; width: 100px;"]

Stock Market News

GSK to buy Sierra Oncology for $1.9 billion

04/13/2022

Less than a minute

2022.04.13 09:41

GSK to buy Sierra Oncology for $1.9 billion
GSK logo is seen in this illustration taken on January 17, 2022. REUTERS/Dado Ruvic/Illustration

(Reuters) – Britain’s GlaxoSmithKline (NYSE:GSK) has agreed to buy California-based biopharmaceutical company Sierra Oncology (NASDAQ:SRRA) in a deal valued at $1.9 billion, the companies said on Wednesday.

Shareholders in Sierra, which focuses on targeted therapies for the treatment of rare forms of cancer, will receive $55 per share of common stock in cash, GSK said.

Source

04/13/2022

Less than a minute